Part VI: IPR & Anemia – An Effective, Low-Cost Tool for Resolving Patent Disputes Since the inter partes review (IPR) process was established under the America Invents Act in 2011, IPR has become a popular and cost-effective tool compared to traditional patent litigation.  Even the U.S. Supreme Court has described the IPR process as a way to […]

Continue Reading

Lawmakers Must Continue to Work with Industry Leaders, Experts to Prevent Manipulations of the U.S. Patent System WASHINGTON D.C. – Today, the Senate Judiciary Subcommittee on Competition Policy, Antitrust, and Consumer Rights held a hearing entitled, “A Prescription for Change: Cracking Down on Anticompetitive Conduct in Prescription Drug Markets” to examine anticompetitive tactics used by many […]

Continue Reading

WASHINGTON, DC – In case you missed it, the Coalition Against Patent Abuse’s Executive Director Matthew Lane penned an op-ed in Morning Consult today on the need to address patent abuse and anti-competitive pricing tactics used by some major pharmaceutical companies.  The U.S. drug system is based on a balance between rewarding innovations with temporary market exclusivity and […]

Continue Reading

WASHINGTON, DC – In the wake of today’s U.S. Supreme Court decision in the United States v. Arthrex Inc. case, the Coalition Against Patent Abuse (CAPA) said that it’s critical for Congress to now address this decision and work to protect and strengthen the Inter Partes Review (IPR) within the U.S. Patent & Trademark Office (USPTO), by ensuring […]

Continue Reading

WASHINGTON D.C. – Matrix Global Advisors (MGA) released a white paper that highlights how patent thickets increase barriers for American patients to access affordable biosimilar medications and treatments.  The paper explains how some biologic manufacturers prevent competition by creating patent walls with “overlapping, weaker” patents to significantly extend their drug’s monopoly and increase profits while limiting access to […]

Continue Reading

WASHINGTON D.C. – The Coalition Against Patent Abuse (CAPA) released the following statement today after the House Committee on Oversight and Reform held a hearing entitled, “Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez,” that focuses on the company’s anti-competitive tactics and pricing strategies that keeps drug prices high for the American healthcare system and […]

Continue Reading

This Report Comes as the U.S. House Oversight and Reform Committee is Set to Hold a Hearing to Investigate Abuses by the Pharmaceutical Industry WASHINGTON D.C. – Recently, the Initiative for Medicines, Access & Knowledge (I-MAK) released a report as part of its “Overpatented, Overpriced” series on the cancer drug Keytruda, highlighting the underhanded tactics used by […]

Continue Reading

Part V: IPR & Ulcerative Colitis – Balancing Innovation and Competition Over the last year, the coronavirus pandemic has caused financial hardships for millions of Americans and our federal government continues to face unprecedented debt.  As recovery efforts are underway, the issue of skyrocketing prescription drug costs remains more prevalent than ever.  A major contributing […]

Continue Reading

Today, some major pharmaceutical companies continue to game the U.S. patent system by limiting generic competition while keeping drug prices high for millions of patients.  Big Pharma’s manipulation of patent laws prevent or delay generic medications from going to market which ultimately denies patients access to more affordable, life-saving, and quality of life enhancing drugs.  […]

Continue Reading

Part III: IPR & Opioid Addiction – Ending Brand Pharma’s Monopoly on Patents Some major pharmaceutical companies have enormous incentives to block market entry of lower-cost, generic drugs for as long as possible.  By taking advantage of certain rules or exploiting legal loopholes that extend a drug’s monopoly far beyond what Congress intended, millions of […]

Continue Reading